Top

Published in:

01-01-2017 | Original Article

Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder

Authors: Akihiro Naito, Satoru Taguchi, Tohru Nakagawa, Akihiko Matsumoto, Yasushi Nagase, Mariko Tabata, Jimpei Miyakawa, Motofumi Suzuki, Hiroaki Nishimatsu, Yutaka Enomoto, Shintaro Takahashi, Toshikazu Okaneya, Daisuke Yamada, Takamitsu Tachikawa, Shigeru Minowada, Tetsuya Fujimura, Hiroshi Fukuhara, Haruki Kume, Yukio Homma

Published in: World Journal of Urology | Issue 1/2017

Abstract

Purpose

Small cell carcinoma of the urinary bladder (SCCB) is known for its aggressive clinical features and poor prognosis. No prognostic factor has been established so far. The aim of this study was to assess the significance of possible prognostic factors, including serum neuron-specific enolase (NSE), an established biomarker for small cell lung carcinoma.

Methods

We retrospectively reviewed 31 patients with primary SCCB treated at our eight affiliate institutions between 2001 and 2014. The association of various clinicopathological factors at diagnosis, including the serum NSE value, with cancer-specific survival (CSS) was assessed. The log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses, respectively.

Results

Nineteen (61.3 %) died of SCCB during the follow-up, with a median survival time of 12.7 months. Prognostic factors were analyzed for the 25 patients after excluding six with missing data. Univariate analysis demonstrated that stage (extensive disease) and serum NSE ≥25 ng/ml were significantly associated with worse CSS. Multivariate analysis identified increased serum NSE value as a sole independent predictor of CSS (hazard ratio 18.52, p = 0.0022).

Conclusions

Serum NSE value at diagnosis was an independent prognostic factor for primary SCCB and may serve as a useful biomarker in the management of SCCB.

Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ (1989) Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer 64:1347–1357CrossRefPubMed

Holmang S, Borghede G, Johansson SL (1995) Primary small cell carcinoma of the bladder: a report of 25 cases. J Urol 153:1820–1822CrossRefPubMed

Lohrisch C, Murray N, Pickles T, Sullivan L (1999) Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 86:2346–2352CrossRefPubMed

Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG (2005) Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol 174:93–96CrossRefPubMed

Choong NW, Quevedo JF, Kaur JS (2005) Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 103:1172–1178CrossRefPubMed

Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG (2005) Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 46:57–63CrossRefPubMed

Bex A, Nieuwenhuijzen JA, Kerst M, Pos F, van Boven H, Meinhardt W, Horenblas S (2005) Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 65:295–299CrossRefPubMed

Mukesh M, Cook N, Hollingdale AE, Ainsworth NL, Russell SG (2009) Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int 103:747–752. doi:10.1111/j.1464-410X.2008.08241.x CrossRefPubMed

Bex A, Sonke GS, Pos FJ, Brandsma D, Kerst JM, Horenblas S (2010) Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: the Netherlands Cancer Institute experience and literature review. Ann Oncol 21:2240–2245. doi:10.1093/annonc/mdq225 CrossRefPubMed

10.

Pasquier D, Barney B, Sundar S et al (2015) Small cell carcinoma of the urinary bladder: a retrospective, multicenter rare cancer network study of 107 patients. Int J Radiat Oncol Biol Phys 92:904–910. doi:10.1016/j.ijrobp.2015.03.019 CrossRefPubMed

11.

Harding M, McAllister J, Hulks G, Vernon D, Monie R, Paul J, Kaye SB (1990) Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance? Br J Cancer 61:605–607CrossRefPubMedPubMedCentral

12.

Johnson PW, Joel SP, Love S, Butcher M, Pandian MR, Squires L, Wrigley PF, Slevin ML (1993) Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 67:760–766CrossRefPubMedPubMedCentral

13.

Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernández JR, Johnson PW, Løber J, Splinter TA, Szturmowicz M (1996) Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 74:463–467CrossRefPubMedPubMedCentral

14.

Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group (2003) The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39:303–313CrossRefPubMed

15.

Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ (2003) Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 39:131–138CrossRefPubMed

16.

Harmsma M, Schutte B, Ramaekers FC (2013) Serum markers in small cell lung cancer: opportunities for improvement. Biochim Biophys Acta 1836:255–272. doi:10.1016/j.bbcan.2013.06.002 PubMed

17.

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon. http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/BB7.pdf. Accessed 10 Dec 2015

18.

Sobin LH, Gospodarowicz MK, Wittekind CH (2009) TNM classification of malignant tumors, 7th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Wiley-Blackwell, New York

19.

Moretto P, Wood L, Emmenegger U et al (2013) Management of small cell carcinoma of the bladder: consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J 7:E44–E56. doi:10.5489/cuaj.220 CrossRefPubMedPubMedCentral

20.

Lynch SP, Shen Y, Kamat A et al (2013) Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 64:307–313CrossRefPubMed

21.

Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, Barocas DA, Chang SS (2014) Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol 191:329–334. doi:10.1016/j.juro.2013.09.009 CrossRefPubMed

22.

Grignon DJ, Ro JY, Ayala AG, Shum DT, Ordóñez NG, Logothetis CJ, Johnson DE, Mackay B (1992) Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer 69:527–536CrossRefPubMed

23.

Soriano P, Navarro S, Gil M, Llombart-Bosch A (2004) Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Arch 445:292–297CrossRefPubMed

24.

Ono A, Naito T, Ito I et al (2012) Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Lung Cancer 76:439–444. doi:10.1016/j.lungcan.2011.12.012 CrossRefPubMed

25.

Carranza OE, Castanon E, Abella LE et al (2013) Clinical management of small-cell carcinoma of the urinary tract: a 10-year single-center’s experience. Clin Genitourin Cancer 11:168–174. doi:10.1016/j.clgc.2012.09.011 CrossRefPubMed

26.

Matsui Y, Fujikawa K, Iwamura H, Oka H, Fukuzawa S, Takeuchi H (2002) Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel. Int J Urol 9:122–124CrossRefPubMed

27.

Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, Horenblas S, Bex A (2013) Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. Int J Urol 20:778–784. doi:10.1111/iju.12038 CrossRefPubMed

28.

Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE (2009) Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 27:2592–2597. doi:10.1200/JCO.2008.19.0256 CrossRefPubMedPubMedCentral

29.

Ismaili N, Heudel PE, Elkarak F, Kaikani W, Bajard A, Ismaili M, Errihani H, Droz JP, Flechon A (2009) Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol 9:4. doi:10.1186/1471-2490-9-4 CrossRefPubMedPubMedCentral

30.

Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U (2014) Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Prostate 74:1691–1696CrossRefPubMed

Title: Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder
Authors: Akihiro Naito
Satoru Taguchi
Tohru Nakagawa
Akihiko Matsumoto
Yasushi Nagase
Mariko Tabata
Jimpei Miyakawa
Motofumi Suzuki
Hiroaki Nishimatsu
Yutaka Enomoto
Shintaro Takahashi
Toshikazu Okaneya
Daisuke Yamada
Takamitsu Tachikawa
Shigeru Minowada
Tetsuya Fujimura
Hiroshi Fukuhara
Haruki Kume
Yukio Homma
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1846-y

At a glance: The STEP trials

Springer Medicine

Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy

Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain

Cost-effectiveness comparison of ureteral calculi treated with ureteroscopic laser lithotripsy versus shockwave lithotripsy

Structured learning for robotic surgery utilizing a proficiency score: a pilot study

Nanomaterials: Friend or foe to male fertility?

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage